查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症奈米技術市場：現況分析與預測（2023-2030）
市場調查報告書
商品編碼
1346736

癌症奈米技術市場：現況分析與預測（2023-2030）

Cancer Nanotechnology Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計從 2023 年到 2030 年，癌症奈米技術市場的複合年增長率將達到約 13.8%。 奈米技術提供了一種直接、選擇性地靶向癌細胞和腫瘤的方法。 這些工具使臨床醫生能夠安全有效地對腫瘤進行化療、放療以及下一代免疫和基因療法。 例如，根據 GLOBOCAN 2020 的數據，2020 年全球癌症患者人數增加至 1,930 萬人，癌症死亡人數增加至 1,000 萬人。 癌症盛行率的增加促進了癌症奈米技術市場的成長。 此外，旨在改善癌症治療和解決罕見疾病的政府措施和政策也促進了市場成長。 2018年，科技部科學家開發了一種生物相容性多孔材料，作為一種多功能載體，無需使用內源性配體（離子或分子）即可將抗癌藥物遞送至腫瘤細胞核，並製備了聚二甲基矽氧烷（PDMS）奈米顆粒。 細胞核含有大部分遺傳物質。 生物活性奈米粒子可以根據體內的因素或治療改變其特性，可以充當體內狀況的動態報告者，並提供有關疾病進展和治療反應的空間和時間資訊。 因此，促進了癌症奈米技術市場的成長。

依類型劃分，市場分為奈米粒子、奈米纖維、奈米棒、石墨烯、奈米流體裝置等。 其中，奈米粒子佔據了很大的市場份額。 這是因為增加藥物傳輸裝置和系統（例如奈米顆粒製劑）對於將藥物輸送到肺部至關重要。 奈米顆粒可以更好地將通常不溶的藥物遞送至局部和遠處的腫瘤部位，從而減少通常與常規藥物治療相關的全身副作用。

根據應用，市場分為診斷、治療和治療診斷。 其中，診斷藥物將在2022年擁有較高的市場份額，並將在預測期內繼續佔據主導地位。 這是因為奈米技術在醫療診斷和成像領域的日益採用正在推動市場需求的成長。 在生物醫學研究中，奈米技術被廣泛用於對抗 COVID-19。 就像許多使用奈米粒子作為基於封裝某些藥物活性成分的治療的疫苗一樣。 已發現許多奈米系統比其傳統的對應物更適合用於治療目的。 因此，這一因素正在推動市場成長。

依癌症類型，市場分為乳癌、胃癌、肺癌等。 其中，乳癌預計將在預測期內獲得較高的市場份額。 由於用於乳癌治療的奈米技術的廣泛應用以及乳癌盛行率的迅速增加，乳癌在市場上佔據了60%以上的份額。

為了更了解奈米藥物的市場介紹，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、法國、義大利、西班牙、英國、歐洲其他地區）、亞太地區（中國、日本、印度和亞太地區的其他國家）根據其在世界各國的全球影響力進行分析。 由於多種因素，癌症奈米技術在北美越來越受歡迎。 由於癌症盛行率不斷上升、醫療保健專業人員和公眾對奈米技術的認識不斷提高、先進成像技術的發展以及治療選擇的增加，北美癌症奈米技術市場預計將增長。 例如，根據 Cancer.net 的數據，2020 年估計有 586,202 人被診斷出患有甲狀腺癌。

強生公司、GE Healthcare、Combimatrix Corporation (Invitae Corporation)、F. Hoffmann-La Roche、Sigma-Tau Pharmaceuticals Inc.、Merck and Company Inc.、輝瑞公司(Pfizer, Inc.)、Nanosphere, Inc. 併購和聯盟也在發生。

目錄

第 1 章市場介紹

  • 市場定義
  • 主要目標
  • 利害關係人
  • 限制

第 2 章研究方法或假設

  • 調查過程
  • 調查方法
  • 受訪者簡介

第 3 章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對癌症奈米科技市場的影響

第 6 章癌症奈米技術市場收入，2020-2030

第 7 章按類型劃分的市場洞察

  • 奈米顆粒
  • 奈米纖維
  • 奈米棒
  • 石墨烯
  • 奈米流體裝置
  • 其他

第 8 章按應用劃分的市場洞察

  • 診斷
  • 治療學
  • 治療診斷學

第 9 章按應用劃分的市場洞察

  • 乳癌
  • 胃癌
  • 肺癌
  • 其他

第 10 章按地區劃分的市場洞察

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 亞太地區的其他國家/地區
  • 世界其他地區

第 11 章癌症奈米技術市場動態

  • 市場促進因素
  • 市場挑戰
  • 影響分析

第 12 章癌症奈米科技市場機會

第 13 章癌症奈米科技市場趨勢

第 14 章需求面與供給面分析

  • 需求方分析
  • 供給面分析

第 15 章價值鏈分析

第 16 章價格分析

第 17 章競爭場景

  • 競爭狀況
    • 波特五力分析

第 18 章公司簡介

  • Abbott
  • GE Healthcare
  • Combimatrix Corporation（Invitae Corporation）
  • Mallinckrodt Plc
  • Sigma-Tau Pharmaceuticals Inc.
  • Merck and Company Inc.
  • Pfizer, Inc.
  • Nanosphere, Inc.（Luminex Corporation）
  • Celgene Corporation
  • Teva Pharmaceutical Industries

第 19 章免責聲明

簡介目錄
Product Code: UMHE212197

The cancer nanotechnology market is expected to register a CAGR of approx. 13.8% over the period of 2023-2030. Nanotechnology offers the means to target therapies directly and selectively for cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. For instance, according to GLOBOCAN, 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. This increasing prevalence of cancer contributes to the growth of the cancer nanotechnology market. Furthermore, government initiatives and policies aimed at improving cancer care and addressing rare diseases have contributed to the growth of the market. In 2018, Scientists at the Department of Science and Technology fabricated highly biocompatible porous polydimethylsiloxane (PDMS) nanoparticles as a versatile vehicle to deliver anti-cancer drugs to the nuclei of tumor cells without utilizing any intrinsic ligands (ions or molecules). The nucleus of any cell contains most of its genetic material. Bioactivatable nanoparticles that modify properties in reaction to factors or procedures within the body act as dynamic reporters of in vivo states and can provide both spatial and temporal information on disease progression and therapeutic response. Hence, boost the growth of cancer nanotechnology market.

Based on type, the market is segmented into nanoparticles, nanofibers, nanorods, graphene, nanofluidic devices, and others. Among these nanoparticles have a significant share of the market. This is because drug delivery devices and systems increased as nanoparticle drug formulations are vital in pulmonary drug delivery. The nanoparticles can deliver the normally insoluble drugs to local and distant tumor sites in a better way, thus reducing the systemic side effects generally associated with traditional drug therapies.

Based on application, the market is segmented into diagnostics, therapeutics, and theranostics. Among these, diagnostics has a high market share in 2022 and will dominate during the forecast period. This is due to the rise in the adoption of nanotechnology in medical diagnosis and imaging is increasing the market growth demand. In biomedical research, nanotechnology is widely used against COVID-19, as in numerous vaccinations that use nanoparticles as a treatment based on the encapsulation of the active ingredient of certain medications. Numerous nanosystems have been found to be better candidates for therapeutic purposes than conventional ones. Thus, this factor boosts market growth.

Based on the cancer type, the market is segmented into breast cancer, stomach cancer, lung cancer, and others. Among this breast cancer will attain a high market share during the forecast period. Breast cancer held more than 60% share in the market owing to the presence of wide range of nanotechnology for the management of breast cancer and the surge in the prevalence of breast cancer.

For a better understanding of the market adoption of nanomedicines, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. Cancer Nanotechnology has gained increasing popularity in North America due to various factors. The North America Cancer Nanotechnology market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of nanotechnology among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to Cancer.net, an estimated 586,202 people were diagnosed with thyroid cancer.

Some of the major players operating Johnson & Johnson, GE Healthcare, Combimatrix Corporation (Invitae Corporation), F. Hoffmann-La Roche, Sigma-Tau Pharmaceuticals Inc., Merck and Company Inc., Pfizer, Inc., Nanosphere, Inc. (Luminex Corporation), Celgene Corporation, and Teva Pharmaceutical Industries among others. Several M&A's along with partnerships have been undertaken.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the CANCER NANOTECHNOLOGY Market
  • 2.2. Research Methodology of the CANCER NANOTECHNOLOGY Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CANCER NANOTECHNOLOGY MARKET

6 CANCER NANOTECHNOLOGY MARKET REVENUE (USD Mn), 2020-2030F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Nanoparticles
  • 7.2. Nanofibers
  • 7.3. Nanorods
  • 7.4. Graphene
  • 7.5. Nanofluidic Devices
  • 7.6. Others

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Diagnostics
  • 8.2. Therapeutics
  • 8.3. Theranostics

9 MARKET INSIGHTS BY APPLICATION

  • 9.1. Breast Cancer
  • 9.2. Stomach Cancer
  • 9.3. Lung Cancer
  • 9.4. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. UK
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. South Korea
    • 10.3.5. Rest of APAC
  • 10.4. Rest of the World

11 CANCER NANOTECHNOLOGY MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.1. Impact Analysis

12 CANCER NANOTECHNOLOGY MARKET OPPORTUNITIES

13 CANCER NANOTECHNOLOGY MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICE ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1. Competitive Landscape
    • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

  • 18.1. Abbott
  • 18.2. GE Healthcare
  • 18.3. Combimatrix Corporation (Invitae Corporation)
  • 18.4. Mallinckrodt Plc
  • 18.5. Sigma-Tau Pharmaceuticals Inc.
  • 18.6. Merck and Company Inc.
  • 18.7. Pfizer, Inc.
  • 18.8. Nanosphere, Inc. (Luminex Corporation)
  • 18.9. Celgene Corporation
  • 18.10. Teva Pharmaceutical Industries

19 DISCLAIMER